Instead of conventional labeling ex vivo in cell culture, mesenchymal stem cells (MSCs) were labeled in vivo with intravenous injection of ferumoxytol (Feraheme; AMAG Pharmaceuticals, Lexington, Mass), a Food and Drug Administration (FDA)-approved intravenous iron supplement. After their isolation and processing from bone marrow, the same MSCs were injected in rats with an osteochondral defect, allowing MR monitoring of their engraftment for at least 4 weeks. This straightforward labeling approach, avoiding several regulatory issues, may accelerate clinical translation of magnetic resonance (MR) imaging for stem cell tracking.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging